Do β-blockers combined with RAS inhibitors make sense after all to protect against renal injury?

Current Hypertension Reports

Volumn 9, Issue 5, 2007, Pages 409-414

  Ritz, Eberhard ^a   Rump, Lars Christian ^b  

^a Nierenzentrum   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CARVEDILOL; CATECHOLAMINE; CELIPROLOL; DILEVALOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIPID; METOPROLOL; MOXONIDINE; PHENOXYBENZAMINE; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR;

ADD ON THERAPY; ADRENERGIC STIMULATION; ALBUMINURIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GLOMERULOSCLEROSIS; HEART DEATH; HEART FAILURE; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY FAILURE; KIDNEY INJURY; MONOTHERAPY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIDE EFFECT; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RATS; RENIN-ANGIOTENSIN SYSTEM;

EID: 36849011458     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0075-6     Document Type: Review

References (55)

1. Epstein M: Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912-919.
2. Zuanetti G, Maggioni AP, Keane W, et al.: Nephrologists neglect administration of betablockers to dialysed diabetic patients. Nephrol Dial Transplant 1997, 12:2497-2500.
3. Bakris GL, Hart P, Ritz E: Beta blockers in the management of chronic kidney disease. Kidney Int 2006, 70:1905-1913.
4. DiBona GF: Neural control of the kidney: past, present, and future. Hypertension 2003, 41:621-624.
5. Ye S, Ozgur B, Campese VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997, 51:722-727.
6. Rump LC, Amann K, Orth S, et al.: Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 2000, 15:1735-1738.
7. Converse RL Jr, Jacobsen TN, Toto RD, et al.: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912-1918.
8. Ligtenberg G, Blankestijn PJ, Oey PL, et al.: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999, 340:1321-1328.
9. Klein IH, Ligtenberg G, Oey PL, et al.: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nepbrol 2001, 12:2427-2433.
10. Hausberg M, Kosch M, Harmelink P, et al.: Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106:1974-1979.
11. Xu J, Li G, Wang P, et al.: Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005, 115:1275-1280.
12. Oberhauser V, Schwertfeger E, Rutz T, et al.: Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. Circulation 2001, 103:1638-1643.
13. Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004, 15:524-537.
14. Keith DS, Nichols GA, Gullion CM, et al.: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
15. Amann K, Rump LC, Simonaviciene A, et al.: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000, 11:1469-1478.
16. Amann K, Nichols C, Tornig J, et al.: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996, 11:1003-1011.
17. Hamar P, Kokeny G, Liptak P, et al.: The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model. Nephron Exp Nephrol 2007, 105:e124-136.
18. Rodriguez-Perez JC, Losada A, Anabitarte A, et al.: Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. J Pharmacol Exp Ther 1997, 283:336-344.
19. Amann K, Koch A, Hofstetter J, et al.: Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001, 60:1309-1323.
20. Vonend O, Oberhauser V, von Kugelgen I, et al.: ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int 2002, 61:1617-1626.
21. Brooks DP, Short BG, Cyronak MJ, et al.: Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol 1993, 109:581-586.
22. Wong VY, Laping NJ, Nelson AH, et al.: Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol 2001, 134:977-984.
23. Jovanovic D, Jovovic D, Mihailovic-Stanojevic N, et al.: Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 2005, 63:446-453.
24. Amann K, Hofstetter J, Campean V, et al.: Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. Virchows Arch 2006, 449:207-214.
25. Jacob S, Rett K, Henriksen EJ: Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998, 11:1258-1265.
26. Yoshikawa T, Port JD, Asano K, et al.: Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996, 17(Suppl B):8-16.
27. Tomita K, Marumo F: Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992, 19(Suppl 1):S97-101.
28. Takeda T, Kohno M, Ishii M, et al.: Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. Eur J Clin Pharmacol 1990, 38(Suppl 2):S158-163.
29. Gehr TW, Tenero DM, Boyle DA, et al.: The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999, 55:269-277.
30. Nowicki M, Szewczyk-Seifert G, Klimek D, et al.: Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 2002, 57:352-358.
31. Cice G, Ferrara L, D'Andrea A, et al.: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
32. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
33. Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026-2033.
34. Jafar TH, Schmid CH, Landa M, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
35. Jafar TH, Stark PC, Schmid CH, et al.: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131-1140.
36. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
37. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
38. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
39. Schwenger V, Ritz E: Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998, 13:3091-3095.
40. Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
41. Lea J, Greene T, Hebert L, et al.: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005, 165:947-953.
42. Rump LC: Secondary rise of albuminuria under AT1-receptor blockade - what is the potential role of aldosterone escape? Nephrol Dial Transplant 2007, 22:5-8.
43. Nagase M, Yoshida S, Shibata S, et al.: Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006, 17:3438-3446.
44. Klein IH, Ligtenberg G, Oey PL, et al.: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003, 14:425-430.
45. Neumann J, Ligtenberg G, Oey L, et al.: Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004, 15:2902-2907.
46. Vonend O, Marsalek P, Russ H, et al.: Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003, 21:1709-1717.
47. Bjorck S, Mulec H, Johnsen SA, et al.: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304:339-343.
48. Hannedouche T, Landais P, Goldfarb B, et al.: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994, 309:833-837.
49. Himmelmann A, Hansson L, Hansson BG, et al.: ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 1995, 4:85-90.
50. Bakris GL, Fonseca V, Katholi RE, et al.: Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005, 46:1309-1315.
51. Koch M, Thomas B, Tschope W, et al.: Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993, 36:1113-1117.
52. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int 2002, 62:1784-1790.
53. Abbott KC, Trespalacios FC, Agodoa LY, et al.: Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004, 164:2465-2471.
54. Wali RK, Iyengar M, Beck G, et al.: Efficacy of carvedilol on heart failure in chronic kidney disease. J Am Soc Nephrol 2006, 17:377A.
55. Pun PH, Smith LRW, Middleton JP: Predictors of survival following cardiac arrest in outpatient hemodialysis clinics. J Am Soc Nephrol 2006, 17:46A.